ZAVENTEM, Belgium--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal ...
Cytopoint is a ready-to-use, sterile solution for injection containing the mAb lokivetmab. It is specifically designed to target and neutralize cIL-31, a key cytokine (protein important in cell to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback